---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-079009"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T05:43:57.891096+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Karyopharm shareholders approve 450,000 share increase to equity plan at annual meeting

## Summary
- Elected Garen G. Bohlin and Zhen Su as Class III directors with 3,066,819 and 3,191,845 votes for, respectively.
- Approved amendment to 2022 equity plan adding 450,000 shares; 2,606,928 for, 1,103,365 against, 344,880 abstain.
- Advisory vote on named executive officer compensation passed: 2,716,951 for, 1,041,611 against, 296,611 abstain.
- Advisory vote on say-on-pay frequency favored every year (3,263,514 votes); Board adopted annual frequency.
- Ratified Ernst & Young as independent auditor for FY2025: 6,237,926 for, 210,714 against, 115,566 abstain.

## SEC filing metadata
- accession: 0000950170-25-079009
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025079009/0000950170-25-079009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025079009/kpti-20250528.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-079009
- JSON: https://secwatch.observer/filing/0000950170-25-079009.json
- Plain text: https://secwatch.observer/filing/0000950170-25-079009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.